Lack of correlation between V3-loop peptide enzyme immunoassay serologic subtyping and genetic sequencing. NLM AIDSLINE Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Lack of correlation between V3-loop peptide enzyme immunoassay serologic subtyping and genetic sequencing.

AIDS. 1998 Aug 20;12(12):1405-12. Unique Identifier : AIDSLINE MED/98394543
Nkengasong JN; Willems B; Janssens W; Cheingsong-Popov R; Heyndrickx L; Barin F; Ondoa P; Fransen K; Goudsmit J; van der Groen G; Department of Microbiology, Institute of Tropical Medicine,; Antwerp, Belgium.


Abstract: OBJECTIVE: To compare the performance of V3-loop peptide enzyme immunoassay (PEIA) methodologies from four different laboratories for subtyping HIV-1, and to determine the causes for the lack of correlation between V3-loop PEIA serotyping and subtyping by sequencing. MATERIALS AND METHODS: Synthetic peptides derived from the amino-acid consensus sequences of the V3-loop of group M strains representing genetic subtypes A-F as well as reference strains were evaluated in PEIA by four different laboratories for their ability to accurately determine the subtype in a panel of 85 sera obtained from persons infected with known HIV-1 subtypes (28 subtype A, 34 subtype B, four subtype C, 10 subtype D, seven subtype F, one each of subtype H and G). Furthermore, the V3 loop of the corresponding virus was compared with the V3 loop of the peptides used in PEIA. RESULTS: The correlation between HIV-1 subtyping by sequencing and V3-loop PEIA from the different laboratories varied considerably for the different HIV-1 subtypes: subtype A (46-68%), B (38-85%), C (75-100%), D (29-50%), and F (17-57%). A 70% agreement between PEIA and sequencing subtypes was observed for samples with the concordant presence of the same octameric sequences in the V3 loop of the virus and the V3 loop of the peptide used in PEIA; however, only 42% of specimens with different V3-loop octameric viral and peptide sequences yielded concordant results in V3-loop serotyping and genetic subtyping. CONCLUSION: Our results indicate that V3-loop PEIA methodologies used in different laboratories correlate poorly with genetic subtyping, and that their accuracy to predict HIV-1 subtypes in sera of Belgian individuals infected with different HIV-1 subtypes (A, B, C, D, F, G and H) vary considerably. The poor correlation between serotyping and genetic subtyping was partly due to the simultaneous occurrence of subtype-specific octameric sequences at the tip of the V3 loop of viruses belonging to different genetic subtypes.
Keywords: JOURNAL ARTICLE MULTICENTER STUDY Amino Acid Sequence Comparative Study *Genes, env Human HIV Antibodies/BLOOD HIV Envelope Protein gp120/*CLASSIFICATION/*GENETICS/IMMUNOLOGY HIV Infections/*VIROLOGY HIV-1/*CLASSIFICATION *Immunoenzyme Techniques Molecular Sequence Data Peptide Fragments/*CLASSIFICATION/*GENETICS/IMMUNOLOGY Serotyping Support, Non-U.S. Gov'tKWDjournalarticlemulticenterstudyaminoacidsequencecomparativestudyKWDgenes,envhumanhivantibodies/bloodhivenvelopeproteingp120/KWDclassification/KWDgenetics/immunologyhivinfections/KWDvirologyhiv-1/KWDclassificationKWDimmunoenzymetechniquesmolecularsequencedatapeptidefragments/KWDclassification/KWDgenetics/immunologyserotypingsupport,non-uKWDsKWDgov't
990130
A9911042

Copyright © 1999 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .